JP7792746B2 - 治療用骨剤の使用方法 - Google Patents

治療用骨剤の使用方法

Info

Publication number
JP7792746B2
JP7792746B2 JP2019563340A JP2019563340A JP7792746B2 JP 7792746 B2 JP7792746 B2 JP 7792746B2 JP 2019563340 A JP2019563340 A JP 2019563340A JP 2019563340 A JP2019563340 A JP 2019563340A JP 7792746 B2 JP7792746 B2 JP 7792746B2
Authority
JP
Japan
Prior art keywords
formulation
patient
mci
composition
doses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019563340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020506239A (ja
JP2020506239A5 (enExample
Inventor
サイモン ジェイミー
アール．フランク キース
Original Assignee
アイジーエル ファーマ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイジーエル ファーマ，インコーポレイティド filed Critical アイジーエル ファーマ，インコーポレイティド
Publication of JP2020506239A publication Critical patent/JP2020506239A/ja
Publication of JP2020506239A5 publication Critical patent/JP2020506239A5/ja
Priority to JP2022164581A priority Critical patent/JP2022183238A/ja
Priority to JP2024209612A priority patent/JP2025036436A/ja
Application granted granted Critical
Publication of JP7792746B2 publication Critical patent/JP7792746B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
    • G21G1/00—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
    • G21G1/02—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes in nuclear reactors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2019563340A 2017-02-08 2018-02-06 治療用骨剤の使用方法 Active JP7792746B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022164581A JP2022183238A (ja) 2017-02-08 2022-10-13 治療用骨剤の使用方法
JP2024209612A JP2025036436A (ja) 2017-02-08 2024-12-02 治療用骨剤の使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762456191P 2017-02-08 2017-02-08
US62/456,191 2017-02-08
PCT/US2018/017082 WO2018148209A1 (en) 2017-02-08 2018-02-06 Method of use for therapeutic bone agents

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022164581A Division JP2022183238A (ja) 2017-02-08 2022-10-13 治療用骨剤の使用方法
JP2024209612A Division JP2025036436A (ja) 2017-02-08 2024-12-02 治療用骨剤の使用方法

Publications (3)

Publication Number Publication Date
JP2020506239A JP2020506239A (ja) 2020-02-27
JP2020506239A5 JP2020506239A5 (enExample) 2021-01-21
JP7792746B2 true JP7792746B2 (ja) 2025-12-26

Family

ID=63107036

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019563340A Active JP7792746B2 (ja) 2017-02-08 2018-02-06 治療用骨剤の使用方法
JP2022164581A Pending JP2022183238A (ja) 2017-02-08 2022-10-13 治療用骨剤の使用方法
JP2024209612A Pending JP2025036436A (ja) 2017-02-08 2024-12-02 治療用骨剤の使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022164581A Pending JP2022183238A (ja) 2017-02-08 2022-10-13 治療用骨剤の使用方法
JP2024209612A Pending JP2025036436A (ja) 2017-02-08 2024-12-02 治療用骨剤の使用方法

Country Status (5)

Country Link
US (1) US11813339B2 (enExample)
EP (1) EP3579886A4 (enExample)
JP (3) JP7792746B2 (enExample)
CA (1) CA3052973C (enExample)
WO (1) WO2018148209A1 (enExample)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006525965A (ja) 2003-05-09 2006-11-16 シエーリング アクチエンゲゼルシャフト 骨局在化放射性薬物及びチューブリン相互作用化合物の組合せ放射線療法
WO2015054173A1 (en) 2013-10-07 2015-04-16 |Sotherapeutics Group, Llc High purity therapeutic bone agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059412A (en) * 1984-06-04 1991-10-22 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors
WO2011149844A1 (en) * 2010-05-24 2011-12-01 Iso Therapeutics Group Llc Delivery of high dose therapeutic radioisotopes to bone
CN105792836A (zh) * 2013-08-28 2016-07-20 施特姆森特克斯股份有限公司 新型sez6调节剂以及应用方法
JP6930922B2 (ja) 2015-05-25 2021-09-01 アイジーエル ファーマ，インコーポレイティド 放射性同位体用ｄｏｔｍｐキット製剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006525965A (ja) 2003-05-09 2006-11-16 シエーリング アクチエンゲゼルシャフト 骨局在化放射性薬物及びチューブリン相互作用化合物の組合せ放射線療法
WO2015054173A1 (en) 2013-10-07 2015-04-16 |Sotherapeutics Group, Llc High purity therapeutic bone agents
JP2016532652A (ja) 2013-10-07 2016-10-20 アイソセラピューティクス グループ リミティド ライアビリティー カンパニーＩｓｏＴｈｅｒａｐｅｕｔｉｃｓ Ｇｒｏｕｐ ＬＬＣ 高純度治療用骨剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Radiotherapy and Oncology, 1997, Vol.43, pp.175-179,

Also Published As

Publication number Publication date
CA3052973A1 (en) 2018-08-16
JP2020506239A (ja) 2020-02-27
JP2022183238A (ja) 2022-12-08
US20210138095A1 (en) 2021-05-13
CA3052973C (en) 2024-02-06
US11813339B2 (en) 2023-11-14
WO2018148209A1 (en) 2018-08-16
EP3579886A4 (en) 2020-11-25
JP2025036436A (ja) 2025-03-14
EP3579886A1 (en) 2019-12-18

Similar Documents

Publication Publication Date Title
KR100671387B1 (ko) 석회화된 조직을 표적으로 하는, 통증 완화, 뼈 암 치료,및 뼈 표면 조절용 라듐-223의 제조 및 용도
US7335154B2 (en) Radiotherapy
AU2001267734A1 (en) Radiotherapy
US10596277B2 (en) High purity therapeutic bone agents
WO2011149844A1 (en) Delivery of high dose therapeutic radioisotopes to bone
JP7792746B2 (ja) 治療用骨剤の使用方法
HK1090750B (en) Methods of preparing radium-223, and pharmaceutically acceptable agents and reagent set

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221013

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221013

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20221025

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221118

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221122

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221228

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251003

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251216